{
    "organizations": [],
    "uuid": "799eea3628acdd216fbfa256f1590bb10cb5b8bf",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/04/25/business-wire-cerus-to-release-first-quarter-2018-results-on-may-8-2018.html",
    "ord_in_thread": 0,
    "title": "Cerus to Release First Quarter 2018 Results on May 8, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq:CERS) announced today that its first quarter results will be released on Tuesday, May 8, 2018, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.\nTo access the live webcast, please visit the Investor Relations page of the Cerus website at http://www.cerus.com/ir . Alternatively, you may access the live conference call by dialing (866) 235-9006 (U.S.) or (631) 291-4549 (international).\nA replay will be available on the company’s website, or by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and entering conference ID number 2366225. The replay will be available approximately three hours after the call through May 22, 2018.\nABOUT CERUS\nCerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development. See http://www.cerus.com for information about Cerus.\nINTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.\nView source version on businesswire.com : https://www.businesswire.com/news/home/20180425005420/en/\nCerus Corporation\nTim Lee, 925-288-6137\nInvestor Relations Director\nSource: Cerus Corporation",
    "published": "2018-04-25T16:30:00.000+03:00",
    "crawled": "2018-04-25T16:52:57.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "concord",
        "business",
        "wire",
        "cerus",
        "corporation",
        "nasdaq",
        "cer",
        "announced",
        "today",
        "first",
        "quarter",
        "result",
        "released",
        "tuesday",
        "may",
        "close",
        "stock",
        "market",
        "company",
        "host",
        "conference",
        "call",
        "webcast",
        "pm",
        "et",
        "afternoon",
        "management",
        "discus",
        "company",
        "financial",
        "result",
        "provide",
        "general",
        "business",
        "overview",
        "outlook",
        "access",
        "live",
        "webcast",
        "please",
        "visit",
        "investor",
        "relation",
        "page",
        "cerus",
        "website",
        "http",
        "alternatively",
        "may",
        "access",
        "live",
        "conference",
        "call",
        "dialing",
        "international",
        "replay",
        "available",
        "company",
        "website",
        "dialing",
        "international",
        "entering",
        "conference",
        "id",
        "number",
        "replay",
        "available",
        "approximately",
        "three",
        "hour",
        "call",
        "may",
        "cerus",
        "cerus",
        "corporation",
        "biomedical",
        "product",
        "company",
        "focused",
        "field",
        "blood",
        "transfusion",
        "safety",
        "intercept",
        "blood",
        "system",
        "designed",
        "reduce",
        "risk",
        "infection",
        "inactivating",
        "broad",
        "range",
        "pathogen",
        "virus",
        "bacteria",
        "parasite",
        "may",
        "present",
        "donated",
        "blood",
        "nucleic",
        "acid",
        "targeting",
        "mechanism",
        "action",
        "intercept",
        "treatment",
        "designed",
        "inactivate",
        "established",
        "transfusion",
        "threat",
        "hepatitis",
        "b",
        "c",
        "hiv",
        "west",
        "nile",
        "virus",
        "bacteria",
        "well",
        "emerging",
        "pathogen",
        "chikungunya",
        "malaria",
        "dengue",
        "cerus",
        "currently",
        "market",
        "sell",
        "intercept",
        "blood",
        "system",
        "platelet",
        "plasma",
        "united",
        "state",
        "europe",
        "commonwealth",
        "independent",
        "state",
        "middle",
        "east",
        "selected",
        "country",
        "region",
        "around",
        "world",
        "intercept",
        "red",
        "blood",
        "cell",
        "system",
        "clinical",
        "development",
        "see",
        "http",
        "information",
        "cerus",
        "intercept",
        "intercept",
        "blood",
        "system",
        "trademark",
        "cerus",
        "corporation",
        "view",
        "source",
        "version",
        "http",
        "cerus",
        "corporation",
        "tim",
        "lee",
        "investor",
        "relation",
        "director",
        "source",
        "cerus",
        "corporation"
    ]
}